Takeshi Masubuchi

414 total citations
16 papers, 339 citations indexed

About

Takeshi Masubuchi is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Immunology. According to data from OpenAlex, Takeshi Masubuchi has authored 16 papers receiving a total of 339 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Pulmonary and Respiratory Medicine, 8 papers in Oncology and 5 papers in Immunology. Recurrent topics in Takeshi Masubuchi's work include Lung Cancer Treatments and Mutations (4 papers), Asthma and respiratory diseases (3 papers) and Neonatal Respiratory Health Research (2 papers). Takeshi Masubuchi is often cited by papers focused on Lung Cancer Treatments and Mutations (4 papers), Asthma and respiratory diseases (3 papers) and Neonatal Respiratory Health Research (2 papers). Takeshi Masubuchi collaborates with scholars based in Japan and United States. Takeshi Masubuchi's co-authors include Akemi Takamizawa, Sekiya Koyama, Keishi Kubo, Sonoko Nagai, Takateru Izumi, Etsuro Sato, Morie Sekiguchi, Richard Robbins, Y. Matsuzawa and Minoru Hasegawa and has published in prestigious journals such as The Journal of Immunology, American Journal of Respiratory and Critical Care Medicine and American Journal Of Pathology.

In The Last Decade

Takeshi Masubuchi

12 papers receiving 326 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Takeshi Masubuchi Japan	8	172	96	79	54	54	16	339
Matthias Hagner Germany	9	154 0.9×	50 0.5×	93 1.2×	81 1.5×	31 0.6×	13	341
Katarzyna Grzela Poland	9	137 0.8×	109 1.1×	59 0.7×	50 0.9×	20 0.4×	36	312
Sussan Kianpour Canada	6	162 0.9×	106 1.1×	105 1.3×	76 1.4×	55 1.0×	6	364
Lovisa Dousha Australia	11	124 0.7×	62 0.6×	139 1.8×	88 1.6×	48 0.9×	15	320
H.C. Raatgeep Netherlands	11	186 1.1×	191 2.0×	145 1.8×	78 1.4×	66 1.2×	16	494
Soichiro Ueda Japan	9	102 0.6×	107 1.1×	51 0.6×	42 0.8×	23 0.4×	25	273
Fen Lan China	12	99 0.6×	69 0.7×	98 1.2×	142 2.6×	47 0.9×	36	394
Axel Klenk Switzerland	6	125 0.7×	66 0.7×	34 0.4×	63 1.2×	49 0.9×	6	288
Sean Mateer Australia	7	86 0.5×	54 0.6×	112 1.4×	156 2.9×	42 0.8×	9	365
Satoshi Ano Japan	11	78 0.5×	141 1.5×	173 2.2×	107 2.0×	70 1.3×	23	367

Countries citing papers authored by Takeshi Masubuchi

Since Specialization

Citations

This map shows the geographic impact of Takeshi Masubuchi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Takeshi Masubuchi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Takeshi Masubuchi more than expected).

Fields of papers citing papers by Takeshi Masubuchi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Takeshi Masubuchi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Takeshi Masubuchi. The network helps show where Takeshi Masubuchi may publish in the future.

Co-authorship network of co-authors of Takeshi Masubuchi

This figure shows the co-authorship network connecting the top 25 collaborators of Takeshi Masubuchi. A scholar is included among the top collaborators of Takeshi Masubuchi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Takeshi Masubuchi. Takeshi Masubuchi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Endo, Satoshi, Hisao Imai, Ayako Shiono, et al.. (2024). The Glasgow Prognostic Score as a Predictor of Survival after Chemoradiotherapy for Limited-Disease Small Cell Lung Cancer. Oncology. 103(2). 1–11.

Kawakita, Daisuke, Hisamaru Hirai, Takeshi Masubuchi, et al.. (2019). Trastuzumab plus docetaxel in patients with advanced HER2-positive salivary duct carcinoma: Exploratory biomarker analyses. Annals of Oncology. 30. v472–v472.

Kobayashi, Takashi, Kazunari Tateishi, Tsutomu Hachiya, et al.. (2019). Clinical analysis of EGFR‐positive non‐small cell lung cancer patients treated with first‐line afatinib: A Nagano Lung Cancer Research Group. Thoracic Cancer. 10(5). 1078–1085. 5 indexed citations

Kawakita, Daisuke, Toshitaka Nagao, Hideaki Hirai, et al.. (2019). Combined androgen blockade in patients with advanced androgen receptor-positive salivary gland carcinoma: Exploratory biomarker analyses. Annals of Oncology. 30. v471–v472.

Harada, Makoto, et al.. (2019). Relationship Between Immunosuppressive Therapy and the Development of Infectious Complications Among Patients with Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis: A Single-center, Retrospective Observational Study. Cureus. 11(9). e5676–e5676. 6 indexed citations

Kuraishi, Hiroshi, et al.. (2019). [Successful Treatment of Squamous Cell Lung Cancer without PD-L1 Expression Using Fourth-Line Nivolumab].. PubMed. 46(5). 917–920.

Fukushima, Toshirou, Takashi Kobayashi, Kazunari Tateishi, et al.. (2018). Phase II study of cisplatin/pemetrexed combined with bevacizumab followed by pemetrexed/bevacizumab maintenance therapy in patients with EGFR-wild advanced non-squamous non-small cell lung cancer. Cancer Chemotherapy and Pharmacology. 81(6). 1043–1050. 4 indexed citations

Hayashi, Masatoshi, Hiroshi Kuraishi, Takeshi Masubuchi, et al.. (2013). A Fatal Case of Relapsing Pneumonia Caused by Legionella pneumophila in a Patient with Rheumatoid Arthritis After Two Injections of Adalimumab. Clinical Medicine Insights Case Reports. 6. 101–6. 3 indexed citations

Koyama, Sekiya, Akemi Takamizawa, Etsuro Sato, et al.. (2001). Cyclophosphamide stimulates lung fibroblasts to release neutrophil and monocyte chemoattractants. American Journal of Physiology-Lung Cellular and Molecular Physiology. 280(6). L1203–L1211. 11 indexed citations

10.

Koyama, Sekiya, E. Sato, Takeshi Masubuchi, et al.. (1999). Procaterol inhibits IL-1β- and TNF-α-mediated epithelial cell eosinophil chemotactic activity. European Respiratory Journal. 14(4). 767–767. 26 indexed citations

11.

Takamizawa, Akemi, Sekiya Koyama, Etsuro Sato, et al.. (1999). Bleomycin Stimulates Lung Fibroblasts to Release Neutrophil and Monocyte Chemotactic Activity. The Journal of Immunology. 162(10). 6200–6208. 22 indexed citations

12.

Sato, Etsuro, Sekiya Koyama, Akemi Takamizawa, et al.. (1999). Smoke extract stimulates lung fibroblasts to release neutrophil and monocyte chemotactic activities. American Journal of Physiology-Lung Cellular and Molecular Physiology. 277(6). L1149–L1157. 50 indexed citations

13.

Sato, Etsuro, Sekiya Koyama, Takeshi Masubuchi, et al.. (1999). Bleomycin stimulates lung epithelial cells to release neutrophil and monocyte chemotactic activities. American Journal of Physiology-Lung Cellular and Molecular Physiology. 276(6). L941–L950. 22 indexed citations

14.

Kubo, Keishi, Yoshitaka Yamazaki, Takeshi Masubuchi, et al.. (1998). Pulmonary Infection with Mycobacterium Avium-intracellulare Leads to Air Trapping Distal to the Small Airways. American Journal of Respiratory and Critical Care Medicine. 158(3). 979–984. 52 indexed citations

15.

Masubuchi, Takeshi, Sekiya Koyama, Etsuro Sato, et al.. (1998). Smoke Extract Stimulates Lung Epithelial Cells to Release Neutrophil and Monocyte Chemotactic Activity. American Journal Of Pathology. 153(6). 1903–1912. 111 indexed citations

16.

Koyama, Sekiya, Etsuro Sato, Takeshi Masubuchi, et al.. (1998). Alveolar type II-like cells release G-CSF as neutrophil chemotactic activity. American Journal of Physiology-Lung Cellular and Molecular Physiology. 275(4). L687–L693. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact